Intranasal ketorolac for pain launched in the US, by Daiichi Sankyo's Luitpold Pharma
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo's US subsidiary Luitpold Pharmaceuticals, through its newly established division known as Regency Therapeutics, has launched the non-steroidal anti-inflammatory drug (NSAID) ketorolac, Sprix (ketorolac tromethamine) nasal spray, for the short term (up to five days) management of moderate to moderately severe pain that requires opioid analgesia.